Completed PHASE3 NCT00003906

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer

Sponsor: AstraZeneca

Updated 7 times since 2017 Last updated: Oct 5, 2015 Started: May 31, 1999 Primary completion: Dec 31, 2005 Completion: Aug 31, 2012

This PHASE3 trial investigates Breast Cancer and is currently completed. AstraZeneca leads this study, which shows 7 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Eli Lilly and Company
NSABP Foundation Inc
National Cancer Institute (NCI)

Data source: NSABP Foundation Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Abington, United States , Adrian, United States , Akron, United States , Albany, United States , Albuquerque, United States , Allentown, United States , Altoona, United States , Amarillo, United States , Ames, United States and 364 more locations